
Can AI Help Us Treat Cancer Without Overtreating Patients? Oliver Bathe, Qualisure Diagnostics
Shownotes
In this episode of Diagnosing Dx, David Filby is joined by Dr Oliver Bathe, Founder and CEO of Qualisure Diagnostics.
After more than 25 years as a surgical oncologist, Oliver moved into diagnostics with a goal of helping clinicians make more precise treatment decisions. That work led to Thyroid GuidePx®, an 82-gene test designed to help identify whether papillary thyroid cancers are at higher or lower risk of recurrence.
But the bigger opportunity goes beyond a single test. Oliver explains how Qualisure developed Molecular deCodeR™, a cloud-based platform designed to help deploy machine-learning-powered molecular diagnostics across laboratories globally without requiring every test to be run in one central lab.
We also discuss decentralising precision oncology, building a transcriptomic foundation model, partnering with diagnostics and pharma companies, and why commercialisation has become the company’s next major focus.
Key takeaways:
🔹 Why many thyroid cancer patients may be treated more aggressively than necessary
🔹 How Thyroid GuidePx® helps assess recurrence risk in papillary thyroid cancer
🔹 Why centralised molecular testing can limit global access to precision oncology
🔹 How Molecular deCodeR™ could enable diagnostic companies to deploy tests across multiple labs and markets
🔹 Why Qualisure is building a foundation model to make transcriptomic diagnostics more reproducible across workflows
Chapters:
01:06 Introduction and Oliver Bathe’s background
03:58 From cancer research to Qualisure Diagnostics
05:29 The overtreatment problem in thyroid cancer
08:26 Why precision oncology needs a decentralised model
11:01 Molecular deCodeR™ and the bigger software opportunity
13:18 Company milestones, partnerships and the $7M raise
19:07 Commercialising the platform globally
24:44 Building the next generation of transcriptomic diagnostics
Guest: Dr Oliver Bathe
Founder & CEO, Qualisure Diagnostics
Professor of Surgery and Oncology, University of Calgary
LinkedIn: https://ca.linkedin.com/in/oliver-bathe-76a84636
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.